Emlyn Samuel, senior policy manager at Cancer Research UK, said: “Nivolumab is a promising new immunotherapy treatment that gives real hope for lung cancer patients, who have until now had very few options. It’s important that patients can access these evidence-based drugs, so we hope that it’s considered for routine use on the NHS as soon as possible.”